Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms

American Journal of Pathology

Volumn 155, Issue 6, 1999, Pages 2029-2041

  Horie, Ryouichi ^a,b   Gattei, Valter ^c   Ito, Kinji ^a   Imajo Ohmi, Shinobu ^a   Tange, Tsuyoshi ^b   Miyauchi, Jun ^d   Pinto, Antonio ^c   Degan, Massimo ^c   De Iuliis, Angela ^c   Mazzocco, Francesca Tassan ^c   Rossi, Francesca Maria ^c   Higashihara, Masaaki ^e   Watanabe, Toshiki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d NATIONAL CHILDREN S HOSPITAL   (Japan)

^e KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG ALVEOLUS MACROPHAGE; LYMPHATIC LEUKEMIA; METABOLIC ACTIVATION; MOLECULAR CLONING; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0032762178     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65522-8     Document Type: Article

References (38)

1. Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85:1-14
2. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68:421-427
3. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962
4. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725
5. Smith CA, Grüss HJ, Davis T, Anderson D Farrah T, Baker E, Southerland GR, Branann CI, Copeland NG, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Alderson M, Falk B, Gimpel S, Gillis S, Din WS, Goodwin RG, Armitage RJ: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73: 1349-1360
6. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994, 83:2045-2056
7. Horie R, Watanabe T: CD30: expression and function in health and disease. Semin Immunol 1998, 10:457-470
8. Younes A, Consoli U, Zhao S, Snell V, Thomas E, Gruss HJ, Cabanillas F, Andreeff M: CD30 ligand is expressed on resting normal and malignant B lymphocytes. Br J Haematol 1996, 93:569-571
9. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Importa S, Juzbasic S, Todesco M, Perin V, Gattei V, Hermann F, Gruss HJ, Carbone A: Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996, 88:3299-3305
10. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, Carbone A, Pinto A: CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997, 89:2048-2059
11. Wiley SR, Goodwin RG, Smith CA: Reverse signaling via CD30 ligand J Immunol 1996, 157:3635-3639
12. Ellis TM, Simms PE, Slivnick DJ, Jäck H-M, Fisher RI: CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993, 151:2380-2389
13. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS: Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity 1995, 2:587-596
14. + T cells from HIV-infected individuals. Immunity 1995, 3:251-255
15. Ishida T, Tojo T, Aoki T, Kobayashi N, Oishi T, Watanabe T, Yamamoto T, Inoue J: TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996, 93:9437-9442
16. Nakano H, Oshima H, Chung W, Williams-Abott L, Ware CF, Yagita H-Okumura K TRAF5, an activator of NF-kappaB, and putative signal transducer for the lymphotoxin-ß receptor. J Biol Chem 1996, 271: 14661-14661
17. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T: Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-kB activation. J Biol Chem 1997, 272:2042-2045
18. Lee SY, Lee SY, Kandala G, Liou M-L, Choi Y: CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci USA 1996, 93:9699-9703
19. Gedrich RW, Gilfillan MC, Ducket CS, Van Dongen JL, Thompson CB: CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996, 271:12852-12858
20. Boucher L-M, Marengere LEM, Lu Y, Thurkral S, Mak TM: Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily Biochem Biophys Res Commun 1997, 233:592-600
21. Horie R, Aizawa S, Nagai M, Ito K, Higashihara M, Ishida T, Inoue J, Watanabe T: A novel domain in the CD30 cytoplasmic tail mediates NF-κB activation. Int Immunol 1998, 10:203-210
22. Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T: A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 1996, 88:2422-2432
23. Rothe G, Schmitz G, Working Group on Flow Cytometry and Image Analysis: Consensus protocol for the flow cytometry immunophenotyping of hematopoietic malignancies. Leukemia 1996, 10:877-895
24. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982, 42:2112-2135
25. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hemerlink HK, Pileri S, Piris MA, Ralfkiaer E, Warnke RA: A revised European American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392
26. van Zaanen HC, Vet RJ, de Jong CM, von dem Borne AE, van Oers MH: A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flow cytometry. Br J Haematol 1995, 91:55-59
27. Chomczynsky P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159
28. Mosialos G, Birkenbach M, Yalamanchili R, van Arsdale T, Ware C, Kief E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995, 80:389-399
29. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D: Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995, 267:1494-1498
30. Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J: Cloning and characterization of a cDNA encoding human homolog of tumor necrosis factor receptor-associated factor 5. Gene 1998, 207:135-140
31. Ponte P, Ng SY, Engel J, Gunning P, Kedes L: Evolutionary conservation in untranslated regions of actin mRNAs: DNA sequence of a human β-actin cDNA. Nucleic Acids Res 1984, 12:1687-1696
32. Kuroda M, Ishida T, Takanashi M, Satoh M, Machinami R, Watanabe T: Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 1997, 151:735-744
33. Armitage P, Berry G: Statistical Methods in Medical Research. London, Blackwell Scientific, 1987
34. Sonenberg N: mRNA translation: influence of the 5′ and 3′ untranslated regions. Curr Opin Genet Dev 1994, 4:310-315
35. Gruss HJ, DaSilva N, Hu ZB, Uphoff CC, Goodwin RG, Drexler HG: Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 1994, 8:2083-2094
36. Kilwinski J, Berger T, Mpalaskas J, Reuter S, Flick W, Kern P: Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease. Clin Exp Immunol 1999, 115:114-119
37. Kikuchi H, Imajo-Ohmi S: Antibodies specific for proteolyzed forms of protein kinase Cα. Biochim Biophys Acta 1995, 1269:253-259
38. Kikuchi H, Imajo-Ohmi S: Activation and possible involvement of calpain, a calcium-activated cysteine protease, in down-regulation of apoptosis of human monoblast U937 cells. Cell Death Differ 1995, 2:195-199